代谢功能障碍相关脂肪性肝病的心血管影响。
Cardiovascular Implications of Metabolic Dysfunction-Associated Fatty Liver Disease.
机构信息
Division of Endocrinology and Metabolic Disease, Department of Internal Medicine, Maastricht University Medical Center, P Debyelaan 25, 6229 HX Maastricht, the Netherlands; CARIM School for Cardiovascular Diseases, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands; Laboratory for Metabolism and Vascular Medicine, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands.
Department of Epidemiology, Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands; NUTRIM School for Nutrition and Translational Research in Metabolism Maastricht University, Universiteitssingel 50, 6229 ER Maastricht, the Netherlands.
出版信息
Endocrinol Metab Clin North Am. 2023 Sep;52(3):459-468. doi: 10.1016/j.ecl.2023.01.002. Epub 2023 Mar 8.
Both nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated fatty liver disease (MAFLD) have been associated with incident cardiovascular disease (CVD), independent of confounders. Causality has recently been inferred by Mendelian randomization studies. Although these findings have contributed to current guidelines that recommend screening for and treatment of cardiovascular risk factors, it not yet clear how to position NAFLD/MAFLD in cardiovascular risk estimation scores and, consequently, which treatment targets should be used. This review aims to provide practical tools as well as suggestions for further research in order to effectively prevent CVD events in patients with NAFLD/MAFLD.
非酒精性脂肪性肝病 (NAFLD) 和代谢相关脂肪性肝病 (MAFLD) 均与心血管疾病 (CVD) 的发生相关，且不受混杂因素影响。孟德尔随机化研究最近推断出了因果关系。尽管这些发现有助于目前的指南建议对心血管危险因素进行筛查和治疗，但尚不清楚如何在心血管风险评估评分中定位 NAFLD/MAFLD，以及应该使用哪些治疗目标。本综述旨在提供实用工具和进一步研究的建议，以便有效地预防 NAFLD/MAFLD 患者的 CVD 事件。
Zotero 插件